Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Vincristine

3 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCPED1632

    04/04/2017

    A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors

    Treatment

    COGAALL1331

    02/01/2016

    Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

    Treatment

    COGAHOD1331

    07/15/2015

    A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents


    Print this page for your doctor